FCE 22101 and FCE 22891: in-vitro antibacterial activity at concentrations simulating human plasma levels following intravenous, intramuscular and oral administration.
The plasma concentrations of FCE 22101 observed following slow intravenous infusions (1 and 4 h), intramuscular injection and after oral administration of the prodrug FCE 22891 were simulated in a glass chamber containing bacterial cultures. The bacteria used were Staphylococcus aureus ATCC 13709, Staph. aureus 2101 (methicillin-resistant), Streptococcus faecium ATCC 8043, Escherichia coli ATCC 12407, Enterobacter cloacae 1321E and Ent. cloacae P99 (cefazolin-resistant). Addition of FCE 22101 was found to result in a reduction in number of all bacterial strains except Str. faecium, with which only bacteriostasis was observed.
Della Bruna
C
C
Farmitalia Carlo Erba, Research and Development, Milan, Italy.
Jabes
D
D
Rossi
R
R
Younes
G
G
Castellani
P
P
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D015780:Carbapenems; D003470:Culture Media; D004754:Enterobacter / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007769:Lactams; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D013211:Staphylococcus aureus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D003470:Culture Media; D007769:Lactams; C041561:FCE 22891; C040033:ritipenem